Compare FET & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FET | IMMX |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.5M | 629.3M |
| IPO Year | 2007 | 2021 |
| Metric | FET | IMMX |
|---|---|---|
| Price | $53.64 | $8.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $19.20 |
| AVG Volume (30 Days) | 124.3K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.64 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $791,474,000.00 | N/A |
| Revenue This Year | $7.35 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $133.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.93 | $1.94 |
| 52 Week High | $65.43 | $11.61 |
| Indicator | FET | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 41.54 |
| Support Level | $48.86 | $8.10 |
| Resistance Level | $63.59 | $8.97 |
| Average True Range (ATR) | 2.65 | 0.75 |
| MACD | -0.28 | -0.09 |
| Stochastic Oscillator | 45.66 | 23.37 |
Forum Energy Technologies Inc is a manufacturing company serving the oil, natural gas, industrial, and renewable energy industries. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. The company operates in two reportable segments: Drilling and Completions, and Artificial Lift and Downhole. Maximum revenue is generated from the Drilling and Completions segment, which offers products used in the drilling process, and other products like hydraulic fracturing pumps, ROVs and trenchers, submarine rescue vehicles, etc. Geographically, the firm generates maximum revenue from the U.S., followed by Canada, Middle East, Europe and Africa, Asia-Pacific, and Latin America.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.